US FDA advisers vote in favor of recommending COVID vaccines target XFG variant

Moderna
Pfizer Inc.

Moderna

MRNA

0.00

Pfizer Inc.

PFE

0.00

May 28 (Reuters) - The U.S. FDA's advisory panel on Thursday voted in favor of recommending that COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant JN.1 lineage XFG variant.

Eight out of nine panel members voted in favor of the recommendation, while one abstained.



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.